Liquid biopsy has gained increasing interest in the growing era of precision medicine as minimally invasive technique. Recent findings demonstrated that detecting minimal or molecular residual disease (MRD) in NSCLC is a challenging matter of debate that need multidisciplinary competencies, avoiding the overtreatment risk along with achieving a significant survival improvement. This review aims to provide practical consideration for solving data interpretation questions about MRD in NSCLC thanks to the close cooperation between biologists and oncology clinicians. We discussed with a translational approach the critical point of view from benchside, bedside and bunchside to facilitate the future applicability of liquid biopsy in this setting. Herein, we defined the clinical significance of MRD, focusing on relevant practical consideration about advantages and disadvantages, speculating on future clinical trial design and standardization of MRD technology.

Gristina, V., La Mantia, M., Peri, M., Iacono, F., Barraco, N., Perez, A., et al. (2022). Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible. CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 182 [10.1016/j.critrevonc.2022.103899].

Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible

Gristina, Valerio;La Mantia, Maria;Peri, Marta;Iacono, Federica;Barraco, Nadia;Perez, Alessandro;Cutaia, Sofia;Anwar, Zubair;Incorvaia, Lorena;Fulfaro, Fabio;Vieni, Salvatore;Pantuso, Gianni;Graceffa, Giuseppa;Russo, Antonio
;
Galvano, Antonio;Bazan, Viviana
2022-12-31

Abstract

Liquid biopsy has gained increasing interest in the growing era of precision medicine as minimally invasive technique. Recent findings demonstrated that detecting minimal or molecular residual disease (MRD) in NSCLC is a challenging matter of debate that need multidisciplinary competencies, avoiding the overtreatment risk along with achieving a significant survival improvement. This review aims to provide practical consideration for solving data interpretation questions about MRD in NSCLC thanks to the close cooperation between biologists and oncology clinicians. We discussed with a translational approach the critical point of view from benchside, bedside and bunchside to facilitate the future applicability of liquid biopsy in this setting. Herein, we defined the clinical significance of MRD, focusing on relevant practical consideration about advantages and disadvantages, speculating on future clinical trial design and standardization of MRD technology.
31-dic-2022
Gristina, V., La Mantia, M., Peri, M., Iacono, F., Barraco, N., Perez, A., et al. (2022). Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible. CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 182 [10.1016/j.critrevonc.2022.103899].
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1040842822003237-main.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 1.35 MB
Formato Adobe PDF
1.35 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/590534
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact